You are here
Unmet Needs and Rationale for Combination Therapies for Primary Care Physicians
for Primary Care Physicians
In this course, you will learn about the rationale for adding a glucagon-like peptide-1 (GLP-1) receptor agonist to basal insulin therapy. The complementary effects of basal insulin–GLP-1 receptor agonist combination therapy will be discussed in terms of glycaemic control, change in body weight, and risk of hypoglycaemia. After completing this course, you will be able to identify patients for whom basal insulin–GLP-1 receptor agonist combination therapy may be a viable option, and also learn some practical tips on how to best manage these patients.
In this round table discussion, Professor Khunti, Dr Hadley-Brown, and Dr Seidu talk about the currently available treatment options for patients with T2D. New treatment options are then discussed, supported by a case study that considers the use of a basal insulin–GLP-1 RA combination therapy.
Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide
On this page, you can access an article and summary belonging to a series of three recent publications specially curated for this course by Professor Khunti. These articles cover the rationale behind combining basal insulin and GLP-1 RA, and the advantages and limitations of the new fixed-ratio basal insulin–GLP-1 RA combination therapy.